The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase III Olympia-3 trial first results: O-CHOP vs R-CHOP in previously untreated DLBCL
Matthew Matasar, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, presents early results from the Phase III OLYMPIA-3 study (NCT06091865) evaluating odronextamab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (O-CHOP) versus rituximab-CHOP (R-CHOP) for previously untreated diffuse large B-cell lymphoma (DLBCL). He discusses dose optimization findings, supporting full-dose odronextamab as the regimen moves toward randomized evaluation. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
